Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Gynecologic 1

Conditions

Neoplasms 4Leukemia, Myeloid, Acute 3Carcinoma 3Small Cell Lung Carcinoma 1Sarcoma, Myeloid 1Myelodysplastic Syndromes 1Leukemia 1Hematologic Diseases 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1Acute Disease 1

Interventions

Cisplatin 24Carboplatin 19Paclitaxel 18pembrolizumab 12Gemcitabine 12Radiotherapy 9Fluorouracil 9Specimen Handling 8Magnetic Resonance Spectroscopy 7cemiplimab 6Platinum 6Nivolumab 6Docetaxel 6Cetuximab 61,2-diaminocyclohexaneplatinum II citrate 6epothilone B 5anlotinib 5Sunitinib 5Pemetrexed 5Oxaliplatin 5Everolimus 5Drug Therapy 5Cyclophosphamide 5Capecitabine 5Bevacizumab 5durvalumab 4Radiotherapy, Intensity-Modulated 4Radiation 4Erlotinib Hydrochloride 4Celecoxib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma × vosaroxin × Clear all
NCT00252382 2018-09-24

Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC

Sunesis Pharmaceuticals

Phase 2 Completed
31 enrolled 6 charts
Thoracic

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00298896 2018-07-26

Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer

Sunesis Pharmaceuticals

Phase 2 Completed
55 enrolled 10 charts
Thoracic

Carcinoma, Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT00408603 2017-07-27

Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer

Sunesis Pharmaceuticals

Phase 2 Completed
183 enrolled 15 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Carcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡